Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.

Scheen, André

doi:10.1016/S2213-8587(20)30079-6

Request a copy

Article (Scientific journals)

Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.

Scheen, André

2020 • In The lancet. Diabetes & endocrinology, 8 (5), p. 350-352

Peer reviewed

Permalink
https://hdl.handle.net/2268/247499

DOI
10.1016/S2213-8587(20)30079-6

PubMed
32333865

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2020 final semaglutide.pdf

Publisher postprint (560.67 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

GLP-1 receptor agonists; Type 2 diabetes; asian population; semaglutide

Disciplines :

Endocrinology, metabolism & nutrition
Pharmacy, pharmacology & toxicology

Author, co-author :

Scheen, André ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

English

Title :

Oral semaglutide in Japanese versus non-Japanese patients with type 2 diabetes.

Publication date :

2020

Journal title :

The lancet. Diabetes & endocrinology

ISSN :

2213-8587

eISSN :

2213-8595

Volume :

Issue :

Pages :

350-352

Peer reviewed :

Peer reviewed

Available on ORBi :

since 18 May 2020

Statistics

Number of views

65 (2 by ULiège)

Number of downloads

1 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

Bibliography

Kristensen, SL, Rorth, R, Jhund, PS, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. Lancet Diabetes Endocrinol 7 (2019), 776–785.
Scheen, AJ, Semaglutide: a promising new glucagon-like peptide-1 receptor agonist. Lancet Diabetes Endocrinol 5 (2017), 236–238.
Avgerinos, I, Michailidis, T, Liakos, A, et al. Oral semaglutide for type 2 diabetes: a systematic review and meta-analysis. Diabetes Obes Metab 22 (2020), 335–345.
Nuhoho, S, Gupta, J, Hansen, BB, Fletcher-Louis, M, Dang-Tan, T, Paine, A, Orally administered semaglutide versus GLP-1 RAs in patients with type 2 diabetes previously receiving 1-2 oral antidiabetics: systematic review and network meta-analysis. Diabetes Ther 10 (2019), 2183–2199.
Yamada, Y, Katagiri, H, Hamamoto, Y, et al. Dose-response, efficacy, and safety of oral semaglutide monotherapy in Japanese patients with type 2 diabetes (PIONEER 9): a 52-week, phase 2/3a, randomised, controlled trial. Lancet Diabetes Endocrinol 8 (2020), 377–391.
Yabe, D, Nakamura, J, Kaneto, H, et al. Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial. Lancet Diabetes Endocrinol 8 (2020), 392–406.
Kim, YG, Hahn, S, Oh, TJ, Park, KS, Cho, YM, Differences in the HbA1c-lowering efficacy of glucagon-like peptide-1 analogues between Asians and non-Asians: a systematic review and meta-analysis. Diabetes Obes Metab 16 (2014), 900–909.
Aroda, VR, Rosenstock, J, Terauchi, Y, et al. PIONEER 1: randomized clinical trial of the efficacy and safety of oral semaglutide monotherapy in comparison with placebo in patients with type 2 diabetes. Diabetes Care 42 (2019), 1724–1732.
Pratley, R, Amod, A, Hoff, ST, et al. Oral semaglutide versus subcutaneous liraglutide and placebo in type 2 diabetes (PIONEER 4): a randomised, double-blind, phase 3a trial. Lancet 394 (2019), 39–50.